BIIB

Q: What is the price of Biogen (BIIB) today?

The price of Biogen (BIIB) today is US$ 146,57, with a variation of -22.28% compared to the last year. The price of Biogen (BIIB) started the year trading around US$ 152,92 and today it is at US$ 146,57. Follow the real-time price chart, the historical price of Biogen (BIIB), and stock data from Ibovespa and international markets.

Q: When does Biogen (BIIB) pay dividends?

Biogen (BIIB) did not distribute dividends in the last year.

Q: Biogen (BIIB) is it worth it?

Currently, Biogen (BIIB) is priced at US$ 146,57, with a P/E of 13,23%, representing a deviation of 18,45% from its historical average P/E. In the last year, the stock showed a variation of -22.28% in its price and distributed US$ 0,00 in dividends, resulting in a Dividend Yield of 0,00%. The total shareholder return was -22,28%.It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

Q: How to buy stocks of Biogen (BIIB)?

Investing in stocks of Biogen (BIIB) can be done in two ways: by buying the stock no exterior. A stock is the original stock, traded on international exchanges. By buying it, you invest with money outside Brazil, which brings greater geographical and currency diversification.BDR is a receipt for that stock, traded on the B3 with reais, through a brazilian brokerage. Although the money remains in Brazil, the BDR still offers diversification, as it represents a foreign company and is linked to the dollar.

Q: How much do 100 stocks of Biogen (BIIB) yield today?

The yield of Biogen (BIIB) was 2,78% in the last month, -22,28% in the last year and -49,72% in the last 5 years (already considering appreciation and dividends).In the last 12 months, the company paid a total of US$ 0,00 in dividends, um Dividend Yield de 0,00%.If you wanted to buy 100 stocks of Biogen (BIIB) today, the total investment would be US$ 14.657,00, based on the current price of US$ 146,57.If past performance were to repeat, the return on your investment would be:In 1 year: US$ 11.391,42In 5 years: US$ 7.369,54In 10 years: 8.366,22It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

Biogen Inc.

Price

US$ 146,57

variation (12m)

-22,28%

p/l

13,23

p/vp

1,33

DIVIDEND YIELD

0,00%

price BIIB

BVMF

BIIB

If you had invested

years ago

6 months

1 year

5 years

10 years

ago, today you would have

ago, today you would have:

*The figure considers the reinvestment of dividends.

Profitability of BIIB

1 month

3 months

1 year

2 years

5 years

10 years

profitability

1 month

2,78%

3 months

9,21%

1 year

-22,28%

2 years

-43,84%

5 years

-49,72%

10 years

-42,92%

real profitability

profitability minus inflation.

1 month

2,78%

3 months

8,81%

1 year

-25,69%

2 years

-48,74%

5 years

-62,84%

10 years

-65,83%

Indicators BIIB

check out the fundamentals of Biogen shares

P/E

13,23

Sector: -3,47 Industry: -3,47

P/SALES RATIO (PSR)

2,31

Sector: -4,23 Industry: -4,23

P/BV

1,33

Sector: 1,89 Industry: 1,89

DIVIDEND YIELD (DY)

0,00%

Sector: - Industry: -

ROA

6,27%

Sector: -63,87% Industry: -63,87%

ROE

10,08%

Sector: -70,87% Industry: -70,87%

ROIC

13,05%

Sector: -2.084,36% Industry: -2.084,36%

NET MARGIN

17,46%

Sector: -41,75% Industry: -41,75%

GROSS MARGIN

76,19%

Sector: 38,19% Industry: 38,19%

OPERATING MARGIN

27,31%

Sector: -41,04% Industry: -41,04%

P/EBITDA

7,62

Sector: -3,65 Industry: -3,65

P/EBIT

9,83

Sector: -3,64 Industry: -3,64

P/ASSET

0,83

Sector: 1,41 Industry: 1,41

BVPS

119,96

Sector: 1,84 Industry: 1,84

EPS

12,09

Sector: -2,20 Industry: -2,20

EQUITY / ASSETS

0,62

Sector: 0,42 Industry: 0,42

CAGR REVENUES 5 YEARS

-5,19%

Sector: - Industry: -

CAGR PROFITS 5 YEARS

-11,66%

Sector: - Industry: -

FAIR PRICE OF Biogen ASSETS ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Price

The Fair Price formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffet's mentor.

Current price

US$ 146,57

Fair Price

US$ 0,00

Upside Potencial de rentabilidade.

23,25%

See Graham's ranking

Because it considers equity value in its calculation, the formula does not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

BIIB indicators history

DRAG THE FRAME TO SEE MORE DATA

Stocks comparator

DRAG THE FRAME TO SEE MORE DATA

	p/l	p/vp	ROE	dy	market value	net margin
JNJ	17,80	5,78	32,50%	2,69%	US$ 453,87 B	27,75%
PFE	16,92	1,75	10,33%	6,25%	US$ 155,60 B	15,13%
ABBV	108,79	-2.966,40	-2.726,81%	2,79%	US$ 409,36 B	6,45%
NVO	16,20	10,21	62,99%	2,83%	US$ 265,17 B	34,74%
MRK	12,67	4,56	36,03%	3,59%	US$ 223,87 B	28,16%
AZN	28,39	5,90	20,79%	1,83%	US$ 264,46 B	16,23%
BMY	17,97	5,29	29,44%	5,41%	US$ 92,49 B	10,71%
GILD	19,99	7,16	35,82%	2,79%	US$ 140,30 B	24,71%
ZTS	24,61	13,09	53,20%	1,32%	US$ 65,16 B	28,00%
HALO	14,26	25,08	175,93%	0,00%	US$ 8,35 B	48,21%
REGN	13,97	2,10	15,06%	0,44%	US$ 63,00 B	31,83%
AMGN	30,70	21,58	70,29%	3,15%	US$ 160,26 B	14,67%
VRTX	28,59	6,03	21,11%	0,00%	US$ 103,65 B	31,22%
MCK	24,89	-106,90	-429,55%	0,40%	US$ 92,26 B	0,97%
CAH	26,56	-13,96	-52,54%	1,31%	US$ 36,76 B	0,60%
ADMA	17,05	8,87	52,03%	0,00%	US$ 3,53 B	43,51%
HRMY	8,91	2,01	22,58%	0,00%	US$ 1,55 B	22,19%

comparison of BIIB with indexes

If you had invested (change) 2 years years ago, ago, today you would have

R$ 1.000,00 in PETR4 you would have R$ 2.294,60

R$ 1.000,00 in LEVE3 you would have R$ 5.240,60

*The value considers the reinvestment of dividends.

Dividend History BIIB

current DY: 0,00%

5-year average DY: 0,00%

no dividend paid in the period.

ABOUT THE COMPANY Biogen

Biogen Inc.

Average user rating I10

4.0 (11 people)

Estados Unidos

47 years

Foundation: 1978

1991

Year of debut on the stock exchange - 34 years

9.100

Employees

The Company Biogen Inc. (Estados Unidos), is listed on Nasdaq with a market value of $ 23,50 Billions, having a net worth of $ 17,63 Billions.

With a total of 9.100 employees, the company is listed in the sector of Health Care and categorized in industry of Biotechnology.

In the last 12 months the Company had a revenue of $ 10,18 Billions, which generated a profit in the amount of $ 1,78 Billion.

As for its main indicators, the Company has a P/E ratio of 13,23, a P/BV ratio of 1,33 and in the last 12 months the Company did not pay dividends.

The Company is traded internationally through the ticker BIIB.

Market value

US$ 23,50 Billions

Net worth

US$ 17,63 Billions

US$ 17.634.000.000,00

Assets

US$ 28,33 Billions

US$ 28.330.200.000,00

Total Number of Shares

147,00 Milhões

147.000.000

Average Daily Trading Volume

US$ 1,68 Million

US$ 1.679.306,00

Sector

Health Care

Industry

Biotechnology

BIIB

BIIB revenue and profits

BIIB results

DRAG THE FRAME TO SEE MORE DATA

BIIB cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

US$ - -0,00% (12M)

P/L

0,00

0,00%

ROE

-893,55%

P/VP

0,00

MCK - McKesson

US$ 763,55 51,69% (12M)

P/L

24,89

0,40%

ROE

-429,55%

P/VP

-106,90

CAH - Cardinal Health

US$ 156,88 42,09% (12M)

P/L

26,56

1,31%

ROE

-52,54%

P/VP

-13,96

JNJ - Johnson & Johnson

US$ 190,72 21,94% (12M)

P/L

17,80

2,69%

ROE

32,50%

P/VP

5,78

MRK - Merck & Co.

US$ 85,99 --18,73% (12M)

P/L

12,67

3,59%

ROE

36,03%

P/VP

4,56

ABBV - AbbVie

US$ 230,50 23,82% (12M)

P/L

108,79

2,79%

ROE

-2.726,81%

P/VP

-2.966,40

PFE - Pfizer

US$ 24,78 --8,77% (12M)

P/L

16,92

6,25%

ROE

10,33%

P/VP

1,75

AZN - AstraZeneca

US$ 84,53 11,61% (12M)

P/L

28,39

1,83%

ROE

20,79%

P/VP

5,90

BFRA - Biofrontera

US$ - -0,00% (12 M)

P/L

0,00

0,00%

ROE

-893,55%

P/VP

0,00

MCK - McKesson

US$ 763,55 51,69% (12 M)

P/L

24,89

0,40%

ROE

-429,55%

P/VP

-106,90

CAH - Cardinal Health

US$ 156,88 42,09% (12 M)

P/L

26,56

1,31%

ROE

-52,54%

P/VP

-13,96

JNJ - Johnson & Johnson

US$ 190,72 21,94% (12 M)

P/L

17,80

2,69%

ROE

32,50%

P/VP

5,78

MRK - Merck & Co.

US$ 85,99 --18,73% (12 M)

P/L

12,67

3,59%

ROE

36,03%

P/VP

4,56

ABBV - AbbVie

US$ 230,50 23,82% (12 M)

P/L

108,79

2,79%

ROE

-2.726,81%

P/VP

-2.966,40

PFE - Pfizer

US$ 24,78 --8,77% (12 M)

P/L

16,92

6,25%

ROE

10,33%

P/VP

1,75

AZN - AstraZeneca

US$ 84,53 11,61% (12 M)

P/L

28,39

1,83%

ROE

20,79%

P/VP

5,90

Frequently Asked Questions

What is the price of Biogen (BIIB) today?

The price of Biogen (BIIB) today is US$ 146,57, with a variation of -22.28% compared to the last year. The price of Biogen (BIIB) started the year trading around US$ 152,92 and today it is at US$ 146,57. Follow the real-time price chart, the historical price of Biogen (BIIB), and stock data from Ibovespa and international markets.

When does Biogen (BIIB) pay dividends?

Biogen (BIIB) did not distribute dividends in the last year.

Biogen (BIIB) is it worth it?

Currently, Biogen (BIIB) is priced at US$ 146,57, with a P/E of 13,23%, representing a deviation of 18,45% from its historical average P/E. In the last year, the stock showed a variation of -22.28% in its price and distributed US$ 0,00 in dividends, resulting in a Dividend Yield of 0,00%. The total shareholder return was -22,28%.

It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

How to buy stocks of Biogen (BIIB)?

Investing in stocks of Biogen (BIIB) can be done in two ways: by buying the stock no exterior. A stock is the original stock, traded on international exchanges. By buying it, you invest with money outside Brazil, which brings greater geographical and currency diversification.

BDR is a receipt for that stock, traded on the B3 with reais, through a brazilian brokerage. Although the money remains in Brazil, the BDR still offers diversification, as it represents a foreign company and is linked to the dollar.

How much do 100 stocks of Biogen (BIIB) yield today?

The yield of Biogen (BIIB) was 2,78% in the last month, -22,28% in the last year and -49,72% in the last 5 years (already considering appreciation and dividends).

In the last 12 months, the company paid a total of US$ 0,00 in dividends, um Dividend Yield de 0,00%.

If you wanted to buy 100 stocks of Biogen (BIIB) today, the total investment would be US$ 14.657,00, based on the current price of US$ 146,57.

If past performance were to repeat, the return on your investment would be:

In 1 year: US$ 11.391,42
In 5 years: US$ 7.369,54
In 10 years: 8.366,22

It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

BIIB

Biogen Inc.

Price

variation (12m)

p/l

p/vp

DIVIDEND YIELD

Profitability of BIIB

check out the fundamentals of Biogen shares

P/E

P/SALES RATIO (PSR)

P/BV

DIVIDEND YIELD (DY)

ROA

ROE

ROIC

NET MARGIN

GROSS MARGIN

OPERATING MARGIN

P/EBITDA

P/EBIT

P/ASSET

BVPS

EPS

EQUITY / ASSETS

CAGR REVENUES 5 YEARS

CAGR PROFITS 5 YEARS

Graham's Fair Price

If you had invested (change) 2 years years ago, ago, today you would have

current DY: 0,00%

5-year average DY: 0,00%

ABOUT THE COMPANY Biogen

Biogen Inc.

Estados Unidos

47 years

1991

9.100

PROFIT X PRICE BIIB

BIIB results

BIIB cash flow

evolution of assets - BIIB

BIIB balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

MRK - Merck & Co.

ABBV - AbbVie

PFE - Pfizer

AZN - AstraZeneca

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

MRK - Merck & Co.

ABBV - AbbVie

PFE - Pfizer

AZN - AstraZeneca

Frequently Asked Questions